

References

- Adroque, HJ, Frazier, MR, Zeluff, B and Suki, WN (1981):** Systemic calciphylaxis revisited. *Am J Nephrol*; 1:177.
- Angelis M, Wong LL, Myers SA and Wong LM (1997):** Calciphylaxis in patients on hemodialysis: A prevalence study. *Surgery*; 122: 1083-89.
- Araya, CE, Fennell, RS, Neiberger, RE and Dharnidharka, VR (2006):** Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. *Clin J Am Soc Nephrol*; 1:1161.
- Arch-Ferrer, JE, Beenken, SW, Rue, LW et al. (2003):** Therapy for calciphylaxis: an outcome analysis. *Surgery*; 134:941.
- Argilés A, Kerr PG, Canaud B, Flavier JL and Mion C (1995):** Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. *Kidney Int*; 43:630-640.
- Au S and Crawford RI (2002):** Three-dimensional analysis of a calciphylaxis plaque: clues to pathogenesis. *J Am Acad Dermatol*; 47:53.
- Baker BL, Fitzgibbons CA and Buescher LS (2007):** Calciphylaxis responding to sodium thiosulfate therapy. *Arch Dermatol*; 143(2): 269-70.
- Bardin T (2003):** Musculoskeletal manifestations of chronic renal failure. *Curr Opin Rheumatol*; 15:48-54.
- Barman Balfour JA and Scott LJ (2005):** Cinacalcet hydrochloride. *Drugs*; 65(2):271-81.

References

- Barri YM, Graves GS and Knochel JP (1997):** Calciphylaxis in a patient with Crohn's disease in the absence of end-stage renal disease. *Am J Kidney Dis*; 29:773-76.
- Basile C, Montanaro A, Masi M et al. (2002):** Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. *J Nephrol*; 15:676.
- Biedunkiewicz B, Tylicki L, Lichodziejewska-Niemierko M, Liberek T and Rutkowski B (2003):** Ozonotherapy in a dialyzed patient with calcific uremic arteriolopathy. *Kidney Int*; 64(1):367-68.
- Binkert C, Demetriou M, Sukhu B, Szweras M, Tenenbaum HC and Dennis JW (1999):** Tenenbaum HC, Dennis JW. Regulation of osteogenesis by fetuin. *J Biol Chem*; 274:28514-28520.
- Blacher J, Guerin AP, Pannier B, Marchais SJ and London GM (2001):** Arterial calcifications, arterial stiffness, and cardiovascular. *J Am Soc Nephrol*; 17:S267-S273, 2006; Vascular Calcifications and Clinical Outcomes S271 risk in end-stage renal disease. *Hypertension*; 38:938-42.
- Bleibel W, Hazar B and Herman R (2006):** A case report comparing various radiological tests in the diagnosis of calcific uremic arteriolopathy. *Am J Kidney Dis*; 48:659.
- Bleyer AJ, Choi M, Igwemezie B et al. (1998):** A case control study of proximal calciphylaxis. *Am J Kidney Dis*; 32:376.
- Block GA (2000):** Prevalence and clinical consequences of elevated Ca X P product in hemodialysis patients. *Clin Nephrol*; 54:318.
- Block GA, Hulbert-Shearon TE, Levin NW and Port FK (1998):** Association of serum phosphorus and calcium _ phosphate product

References

with mortality risk in chronic hemodialysis patients: A national study. *Am J Kidney Dis*; 31:607-17.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG and Chertow GM (2004): Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol*; 15:2208-18.

Block GA, Raggi P, Bellasi A, Kooienga L and Spiegel DM (2007): Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. *Kidney Int*; 71:438-41.

Boden WE, O'rourke RA and Teo KK (2007): Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med*.

Bogdonoff MD, Engel FL, White JE and Woods AH (1956): Hyperparathyroidism. *Am J Med*; 21:583-95.

Bosler DS, Amin MB, Gulli F and Malhotra RK (2007): Unusual case of calciphylaxis associated with metastatic breast carcinoma. *Am J Dermatopathol*; 29:400-403.

Bostrom K, Watson KE, Horn S, Wortham C, Herman IM and Demer LL (1993): Bone morphogenic protein expression in human atherosclerotic lesions. *J Clin Invest*; 91:1800-809.

Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E and Luft FC (1996): Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. *Am J Kidney Dis*; 27:394-401.

Brouns K, Verbeken E, Degreef H, Bobbaers H and Blockmans D (2007): Fatal calciphylaxis in two patients with giant cell arteritis. *Clin Rheumatol*; 26:836-40.

References

- Budisavljevic MN, Cheek D and Ploth DW (1996):** Calciphylaxis in chronic renal failure. *J Am Soc Nephrol*; 7:978.
- Buxtorf K, Cerottini JP and Panizzon RG (1999):** Lower limb skin ulcerations, intravascular calcifications and sensorimotor polyneuropathy: Calciphylaxis as part of a hyperparathyroidism? *Dermatology*; 198:423-25.
- Campanelli A, Kaya G, Masouye I and Borradori L (2005):** Calcifying panniculitis following subcutaneous injections of nadroparin- calcium in a patient with osteomalacia. *Br J Dermatol* 153:657-60.
- Cardus A, Panizo S, Parisi E, Fernandez E and Valdivielso JM (2005):** Effects of calcitriol and paricalcitol on VSMC proliferation and calcification [Abstract]. *J Am Soc Nephrol*; 16:496A.
- Chan YL, Mahony JF, Turner IJ (1988):** The vascular lesions associated with skin necrosis in renal disease. *Br Dermatol*; 109:85-95.
- Chavel SM, Taraszka KS, Schaffer JV, Lazova R and Schechner JS (2004):** Calciphylaxis associated with acute, reversible renal failure in the setting of alcoholic cirrhosis. *J Am Acad Dermatol*; 50: S125-S28.
- Chen NX, O'Neill KD, Duan D and Moe SM (2002):** Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. *Kidney Int*; 62:1724-31.
- Chen XN, O'Neil KD, Koczman JJ, Duan D and Moe SM (2003):** Role of bone morphogenic proteins (BMPs) in uremic serum induced Cbfa1 expression and mineralization in bovine vascular smooth muscle cells (BVSMC). *J Am Soc Nephrol. Abstract*; 14:691.

References

Chertow GM, Burke SK and Raggi P (2002): Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int*; 62:245-52.

Chertow GM, Burke SK, and Raggi P (2002): Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int* 62: 245–252.

Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK and Toto RD (2003): The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. *AM J Nephrol* (CrossRef)(Medline)(Order article via Infotrieve); 23:307-314.

Cicone JS, Petronis JB, Embert CD and Spector D (2004): Successful treatment of calciphylaxis with intravenous sodium thiosulfate. *Am J Kidney Dis*; 43(6):1104-108.

Coates T, Kirkland GS and Dymock RB (1998): Cutaneous necrosis from calcific arteriopathy. *Am J Kidney Dis*; 32: 384–391.

Couto FM, Chen H, Blank RD and Drezner MK (2006): Calciphylaxis in the absence of end-stage renal disease. *Endocr Pract*; 12:406-10.

Cowper SE (2003): Nephrogenic fibrosing dermopathy: the first 6 years. *Curr Opin Rheumatol* ; 15:785.

Cozzolino M, Dusso AS and Slatopolsky E (2001): Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. *J Am Soc Nephrol*; 12:2511-16.

Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS and Slatopolsky E (2003): Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. *Kidney Int*; 64:1653-61.

References

- Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, and Rosen C (2002):** Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. *Endocr Rev* 23: 570–578.
- Dahl PR, Winkelmann RK and Connolly SM (1995):** The vascular calcification-cutaneous necrosis syndrome. *J Am Acad Dermatol* 33: 53-58.
- Dao HH, Essalihi R, Graillon JF, Lariviere R, De Champlain J, and Moreau P (2002):** Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension. *J Hypertens* 20: 1597–1606.
- De Roma I, Filotico R, Cea M, Procaccio P and Perosa F (2004):** Calciphylaxis in a patient with POEMS syndrome without renal failure and/or hyperparathyroidism: A case report. *Ann Ital Med Int*; 19:283-87.
- Demetriou M, Binkert C, Sukhu B, Tenenbaum HC and Dennis JW (1996):** Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. *J Biol Chem* 271:12755-12761.
- Dereure O, Leray H, Barneon G, Canaud B, Mion C and Guilhou JJ (1996):** Extensive necrotizing livedo reticularis in a patient with chronic renal failure, hyperparathyroidism and coagulation disorder: regression after subtotal parathyroidectomy. *Dermatology*; 192(2): 167-70.
- Don BR and Chin AI (2003):** A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. *Clin Nephrol*; 59:463.

References

- Edmonds ME, Morrison N, Laws JW and Watkins PJ (1982):** Medial arterial calcification and diabetic neuropathy. *Br Med J Clin Res Ed*; 284(6320):928-30.
- Eifinger F, Wahn F, Querfeld U, Pollok M, Gevargez A, Kriener P and Gronemeyer D (2000):** Coronary artery calcifications in children and young adults treated with renal replacement therapy. *Nephrol Dial Transplant*; 15:1892-94.
- Emohare O, Kowal-Vern A, Wiley D and Latenser B (2004):** Vacuum-assisted closure use in calciphylaxis. *J Burn Care Rehabil*; 25(2):161-64.
- Essalihi R, Dao HH, Yamaguchi N, and Moreau P (2003):** A new model of isolated systolic hypertension induced by chronic warfarin and vitamin K(1) treatment. *Am J Hypertens* 16: 103-110.
- Essary LR and Wick MR (2000):** Cutaneous calciphylaxis. An underrecognized clinicopathologic entity. *Am J Clin Pathol*; 113:280.
- Fader DJ and Kang S (1996):** Calciphylaxis without renal failure. *Arch Dermatol* 132: 837-38.
- Fader DJ and Sang S (1998):** Calciphylaxis without renal failure, *Arch Dermatol*; 132:873-878.
- Ferreres JR, Marcoval J, Bordas X, Moreno A, Muniesa C, Prat C and Peyrı J (2006):** Calciphylaxis associated with alcoholic cirrhosis. *J Eur Acad Dermatol Venereol*; 20:599-601.
- Fine A and Zacharias J (2002):** Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapy. *Kidney Int*; 61:2210.

References

- Fischer AH and Morris DJ (1995):** Pathogenesis of Calciphylaxis: Study of three cases with literature review. *Hum Pathol*; 26:1055.
- Floege J (2004):** When man turns to stone: Extraosseous calcification in uremic. *Kidney Int*; 65:2447.
- Foley RN and Parfrey PS (1998):** Cardiovascular disease and mortality in ESRD. *J Nephrol*; 11:239-45.
- Foley RN, Parfrey PS and Sarnak MJ (1998):** Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am Journal of Kidney Diseases*; 32:S112-S119.
- Friedman SG (2002):** Leg revascularization in patients with calciphylaxis. *Am Surg*; 68:591.
- Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE and Schwartz SM (1993):** Osteopontin is elevated during neointima formation formation in rat arteries and is a novel component of human atherosclerotic plaques. *J Clin Invest*; 92:1686-96.
- Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K and Morii H (2001):** Vascular calcification and inorganic phosphate. *Am J Kidney Dis*; 38[Suppl.1]:S34-S37.
- Goff HW and Grimwood RE (2005):** A case of calciphylaxis and chronic myelomonocytic leukemia. *Cutis*; 75:325-28.
- Goldsmith D, Ritz E and Covic A (2004):** Vascular calcification: A stiff challenge for the nephrologists. Does preventing bone disease cause arterial disease? *Kidney Int*; 66:1315-33.
- Goli AK, Goli SA, Shah LS, Byrd RP and Roy TM (2005):** Calciphylaxis: A rare association with alcoholic cirrhosis. Are deficiencies in protein C and S the cause? *South Med J*; 98:736-39.

References

- Golitz LE and Field JP (1972):** Metastatic calcification with skin necrosis. Arch Dermatol; 106:398-402.
- Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM and Salusky IB (2000):** Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med; 342:1478-83.
- Goyal S, Huhn KM and Provost TT (2000):** Calciphylaxis in a patient without renal failure or elevated parathyroid hormone: possible aetiological role of chemotherapy. Br J Dermatol; 143:1087.
- Guerin AP, London GM, Marchais SJ and Metivier F (2000):** Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant; 15:1014-21.
- Hackett BC, McAleer MA, Sheehan G, Powell FC and O'Donnell BF (2008):** Calciphylaxis in a patient with normal renal function: response to treatment with sodium thiosulfate. Clin Exp Dermatol.
- Hafner J, Keusch G, Wahl C et al. (1995):** Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called Calciphylaxis); a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol; 33: 954-962.
- Hanafusa T, Yamaguchi Y, Tani M, Umegaki N, Nishimura Y and Katayama I (2007):** Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates. J Am Acad Dermatol; 57(6):1021-25.
- Hayden MR, Goldsmith D, Sowers JR and Khanna R (2008):** Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol; 40(2):443-51.

References

- Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, Renne T, and Jahn-Dechent W (2003):** Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A: Formation of colloidal calciprotein particles. *J Biol Chem* 278: 13333–13341.
- Huang L, Xu J, Kumta SM and Zheng MH (2001):** Gene expression of glucocorticoid receptor a and b in giant cell tumour of bone: Evidence of glucocorticoid-stimulated osteoclastogenesis by stromal-like tumour cells. *Mol Cell Endocrinol*; 181:199-206.
- Hujairi NM, Afzali B and Goldsmith DJ (2004):** Cardiac calcification in renal patients: what we do and don't know. *Am J Kidney Dis* (CrossRef) (Medline) (Order article via Infotrieve) ; 43:234-243.
- Hunt JL, Fairman R, Mitchell ME, Carpenter JP, Golden M, Khalapyan T, Wolfe M, Neschis D, Milner R, Scoll B, Cusack A, Mohler ER 3rd (2002):** Bone formation in carotid plaques: A clinicopathological study. *Stroke*; 33:1214-19.
- Jahn-Dechent W, Schafer C, Heiss A and Grotzinger J (2001):** Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin. *Z Kardiol* (Medline) (Order article via Infotrieve); 90(suppl 3):47-56.
- Janigan DT, Hirsch DJ, Klassen GA and MacDonald AS (2000):** Calcified subcutaneous arterioles with infarcts of the subcutis and skin ("calciophylaxis") in chronic renal failure. *Am J Kidney Dis*; 35:588.
- Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H and Giachelli CM (2000):** Phosphate regulation of vascular smooth muscle cell calcification. *Circ Res*; 87:E10-E17.

References

- Jono S, Nishizawa Y, Shioi A and Morii H (1998):** 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. *Circulation*; 98:1302-306.
- Kang AS, McCarthy JT, Rowland C (2000):** Is calciphylaxis best treated surgically or medically? *Surgery*; 128:967.
- Kent RB and Lylerly RT (1999):** Systemic calciphylaxis. *South Med J*; 87:278.
- Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnke-Dechent W and Floege J (2003):** Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A crosssectional study. *Lancet*; 361(9360):827-33.
- Ketteler M, Gross ML and Ritz E (2005):** Calcification and cardiovascular problems in renal failure. *Kidney Int Suppl*; 94:S120-S27.
- Khafif RA, Delima C, Silverberg A, Frankel R and Groopman J (1989):** Acute hyperparathyroidism with systemic calcinosis. Report of a case. *Arch Intern Med*; 149:681-84.
- Khoruts A, Stahnke L, McClain CJ, Logan G and Allen JI (1991):** Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. *Hepatology*; 13:267-76.
- Korkmaz C, Dünder E and Zubaroglu I (2002):** Calciphylaxis in a patient with rheumatoid arthritis without renal failure and hyperparathyroidism: The possible role of long-term steroid use and protein S deficiency. *Clin Rheumatol*; 21:66-69.

References

- Kutlu NO, Aydin NE, Aslan M, Bulut T and Ozgen U (2003):** Malignant melanoma of the soft parts showing calciphylaxis. *Pediatr Hematol Oncol*; 20:141-46.
- Lehto S, Niskanen L, Suhonen L, Ronnema T, and Laakso M (1996):** Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. *Arterioscler Thromb Vasc Biol* 16: 978–983.
- Levin A, Mehta RL and Goldstein MB (1993):** Mathematical formulation to help identify the patient at risk of ischemic tissue necrosis -A potentially lethal complication of chronic renal failure. *Am J Nephrol*; 13:448.
- Lim SP, Batta K and Tan BB (2003):** Calciphylaxis in a patient with alcoholic liver disease in the absence of renal failure. *Clin Exp Dermatol*; 28:34-36.
- Llach F (1998):** Calcific uremic arteriolopathy (calciphylaxis): an evolving entity? *Am J Kidney Dis*; 32:384-391.
- London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B and Adda H (2003):** Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. *Nephrol Dial Transplant*; 18:1731-40.
- London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H and Safar ME (2001):** Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. *J Am Soc Nephrol*; 12:2759-67.
- Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D and Rodriguez M (2006):** Calcimimetic R-568 decreases

References

extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol; 17:795-804.

Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, and Rodriguez M (2006): Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 17: 795–804.

Luo G DP, McKee MD, Pinero GJ, Loyer E, Behringer RR and Karsenty G (1997): Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature; 386(6):78-81.

Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ and Onyia JE (2001): Catabolic effects of continuous human PTH in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology; 142:4047-54.

Massry SG, Gordon A, Coburn JW, et al. (1970): Vascular calcification and peripheral necrosis in a renal transplant recipient Reversal of lesions following subtotal parathyroidectomy. Am J Med; 49(3): 416-22.

Mastruserio DN, Nguyen EQ, Nielsen T, Hessel A and Pellegrini AE (1999): Calciphylaxis associated with metastatic breast carcinoma. J Am Acad Dermatol; 41:295-98.

Mataic D and Bastani B (2006): Intraperitoneal sodium thiosulfate for the treatment of calciphylaxis. Ren Fail; 28(4):361-63.

Mazhar AR, Johnson RJ, Gillen D et al. (2001): Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int; 60:324.

References

- Mazzaferro S, Coen G, Bandini S, Borgatti PP, Ciaccheri M, Diacinti D, Ferranti E, Lusenti T, Mancini G, Monducci I, et al. (1993):** Role of ageing, chronic renal failure and dialysis in the calcification of mitral annulus. *Nephrol Dial Transplant*; 8:335-40.
- Meissner M, Kaufmann R and Gille J (2007):** Sodium thiosulphate: A new way of treatment for calciphylaxis? *Dermatology*; 214:278-82.
- Mirza I, Chaubay D, Gunderia H, Shih W and El-Fanek H (2001):** An 1142 *Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol*; 3:1139-43, 2008; Unusual presentation of calciphylaxis due to primary hyperparathyroidism. *Arch Pathol Lab Med*; 125:1351-53.
- Mitterbauer C, Schwarz C, Haas M and Oberbauer R (2006):** Effects of bisphosphonates on bone loss in the first year after renal transplantation: A meta-analysis of randomized controlled trials. *Nephrol Dial Transplant*; 21:2275-81.
- Moe SM and Drueke TB (2003):** Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. *Am J Nephrol* (CrossRef) (Medline) (Order article via Infotrieve) ; 23:369-379.
- Moe SM, Duan D, Doehle BP, O'Neill KD and Chen NX (2003):** Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. *Kidney Int*; 63:1003-11.
- Moe SM, O'Neill KD, Fineberg N, Persohn S, Ahmed S, Garrett P and Meyer CA (2003):** Assessment of vascular calcification in ESRD patients using spiral CT. *Nephrol Dial Transplant* 18:1152-1158.
- Moe SM, O'Neill KD, Resterova M, Fineberg N, Persohn S and Meyer CA (2004):** Natural history of vascular calcification in

References

dialysis and transplant patients. *Nephrol Dial Transplant* 19:2387-2393.

Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N and Kopecky K (2002): Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. *Kidney Int*; 61:638-47.

Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG and Kaplan FS (2001): Bone formation and inflammation in cardiac valves. *Circulation*; 103:1522-28.

Monney P, Nguyen QV, Perroud H and Descombes E (2004): Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. *Nephrol Dial Transplant*; 19(8):2130-32.

Mosca L, Banka CL, Benjamin EJ, et al. (2007): Evidence-based guidelines for cardiovascular disease prevention in women.

Motro M, and Shemesh J (2001): Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. *Hypertension* 37: 1410–1413.

Munavalli G, Reisenauer A, Moses M, Kilroy S and Arbiser JL (2003): Weight loss-induced calciphylaxis: Potential role of matrix metalloproteinases. *J Dermatol*; 30:915-19.

Musso CG, Enz P, Vidal F, et al. (2008): Oral sodium thiosulfate solution as a secondary preventive treatment for calciphylaxis in dialysis patients. *Saudi J Kidney Dis Transpl*; 19(5):820-21.

Mwipatayi BP, Cooke C, Sinniah RH, Abbas M, Angel D and Sieunarine K (2007): Calciphylaxis: Emerging concept in vascular patients. *Eur J Dermatol*; 17:73-78.

References

- Naves M, Guinsburg A, Marelli C, Fernandez-Marti'n JL, Alvarez-Hernandez D, Passlick-Deetjen J and Cannata-Andia J (2006):** Oral active vitamin D and hemodialysis (HD) survival in a large cohort from Latin America. The CORES study. J Am Soc Nephrol; in press.
- Naves M, Guinsburg A, Marelli C, Tejada J, Silvestri F, Passlick-Deetjen J and Cannata-Andia J (2005):** Relative risk (RR) of death according to serum Ca, P and PTH. Results from a large sample of dialysis patients from Latin America followed for up to 54 months. The CORES Study. J Am Soc Nephrol; 16:728A.
- Nigwekar SU (2007):** An unusual case of nonhealing leg ulcer in a diabetic patient. South Med J; 100:851-52.
- Nigwekar SU, Wolf M, Sterns RH and Hix JK (2008):** Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol; 3:1139.
- Nigwekar SU, Wolf M, Sterns RH, and Hix JK, (2008):** Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 1139-43.
- Nissenson A (1998):** Peritoneal dialysis case forum. Perit Dial Int; 18:546.
- Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, and Nihei H (2004):** Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44: 680–688.
- Norris B, Vaysman V and Line BR (2005):** Bone scintigraphy of calciphylaxis: a syndrome of vascular calcification and skin necrosis. Clin Nucl Med; 30:725.

References

- Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O and Schaefer F (2002):** Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. *Circulation* 106:100-105.
- Olson JC, Edmundowicz D, Becker DJ, Kuller LH, and Orchard TJ (2000):** Coronary calcium in adults with type 1 diabetes: A stronger correlate of clinical coronary artery disease in men than in women. *Diabetes* 49: 1571–1578.
- Ozbalkan Z, Calguneri M, Onat AM and Ozturk MA (2005):** Development of calciphylaxis after long-term steroid and methotrexate use in a patient with rheumatoid arthritis. *Intern Med*; 11:1178-81.
- Parhami F, Basseri B, Hwang J, Tintut Y and Demer LL (2002):** Highdensity lipoprotein regulates calcification of vascular cells. *Circ Res*; 91:570-76.
- Podymow T, Wherrett C and Burns KD (2001):** Hyperbaric oxygen in the treatment of calciphylaxis: a case series. *Nephrol Dial Transplant*; 16:2176.
- Pollock B, Cunliffe WJ and Merchant WJ (2000):** Calciphylaxis in the absence of renal failure. *Clin Exp Dermatol*; 25:389-92.
- Price PA, Caputo JM and Williamson MK (2002):** Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: Biochemical evidence for the cancellous bone-remodeling compartment. *J Bone Miner Res*; 17:1171-79.
- Price PA, Faus SA, and Williamson MK (2001):** Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses

References

comparable to those that inhibit bone resorption. *Arterioscler Thromb Vasc Biol* 21: 817–824.

Price PA, June HH, Buckley JR and Williamson MK (2001): Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. *Arterioscler Thromb Vasc Biol*; 21:1610-16.

Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, and Weissberg PL (2000): Apoptosis regulates human vascular calcification in vitro: Evidence for initiation of vascular calcification by apoptotic bodies. *Circ Res* 87: 1055–1062.

Proudfoot D, Skepper JN, McNair R, Johannides A, Weissberg PL and Shanahan CM (2004): Mineral ion-induced release of mineralization-competent matrix vesicles from human vascular smooth muscle cells. *Cardiovasc Pathol*; 13[Suppl.3]:S186.

Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK and Chertow GM (2002): Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? *J Am Coll Cardiol*; 39:695-701.

Raper RF and Ibels LS (1985): Osteosclerotic myeloma complicated by diffuse arteritis, vascular calcification and extensive cutaneous necrosis. *Nephron*; 39:389-92.

Raymond CB and Wazny LD (2008): Sodium thiosulfate, bisphosphonates and cinacalcet for treatment of calciphylaxis. *Am J Health Syst Pharm*; 65(15):1419-29.

Riegert-Johnson DL, Kaur JS and Pfeifer EA(2001): Calciphylaxis associated with cholangiocarcinoma treated with low-molecular-weight heparin and vitamin K. *Mayo Clin Proc* 76:749-52.

References

- Robinson MR, Augustine JJ and Korman NJ (2007):** Cinacalcet for the treatment of calciphylaxis. Arch Dermatol; 143(2):152-54.
- Rodriguez GM, Naves DM and Cannata AJB (2005):** Bone metabolism, vascular calcifications and mortality: Associations beyond mere coincidence. J Nephrol; 18:458-63.
- Rodriguez-Garcia M, Gomez Alonso C, Naves Diaz M, Gago E, Cespedes M, Megido J, Forascepi R, Cannata Andia JB(2004):** Vascular calcification, bone mass, vertebral fractures and mortality in haemodialysis patients [Abstract]. J Am Soc Nephrol 15: 175A, 2004.
- Roe SM, Grahan LD, Brock WB and Barker DE (1994):** Calciphylaxis: Early recognition and management. Am Surg; 60:81.
- Roger NM, Silberman JD, Collins AG, Gershwin LA, Johnson PJ (2007):** Calcific uremic arteriodopathy, advances in pathogenesis and treatment. Semin Dial; 20:150-157.
- Russell R, Brookshire MA, Zekonis M and Moe SM (2002):** Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care. Clin Nephrol; 58:238.
- Russo D, Palmiero G, De Blasio AP, Balletta MM and Andreucci VE (2004):** Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis; 44:1024-30.
- Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Hohne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R**

References

and Nurnberg P (2003): Mutations in ENPP1 are associated with “idiopathic” infantile arterial calcification. *Nat Genet*; 34:379-81.

Sarnak MJ, Levey AS, Schoolwerth AC, Coresth J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfery P, Pferrer M, Raij L, Spinosa DJ and Wilson PW (2003): Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation*; 108:2154-2169.

Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Ester W, Schinke T and Jahnen-Dechent W (2003): The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin -A is a systemically acting inhibitor of ectopic calcification. *J Clin Invest (CrossRef)(Medline)(Order article via Infotrieve)*; 112: 357-366.

Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W and Jahnen-Dechent W (1996): The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and ca homeostasis. *J Biol Chem*; 271:20789-20796.

Schliep S, Schuler G and Kiesewetter F (2008): Successful treatment of calciphylaxis with pamidronate. *Eur J Dermatol*; 18(5):554-56.

Schmermund A, Baumgart D, Mohlenkamp S, Kriener P, Pump H, Gronemeyer D, Seibel R, and Erbel R (2001): Natural history and topographic pattern of progression of coronary calcification in symptomatic patients: An electron-beam CT study. *Arterioscler Thromb Vasc Biol*; 21: 421–426.

References

- Schoen FJ, Tsao JW and Levy RJ (1986):** Calcification of bovine pericardium used in cardiac valve bioprotheses. *Am J Pathol*; 123:134-45.
- Selye H (1962):** Calciphylaxis. Chicago: University of Chicago; 1-16.
- Sewell LD, Weenig RH, Davis MD, McEvoy MT and Pittelkow MR (2004):** Low-dose tissue plasminogen activator for calciphylaxis. *Arch Dermatol*; 140(9):1045-48.
- Shanahan CM (2005):** Mechanisms of vascular calcification in renal disease. *Clin Nephrol*; 63:146-57.
- Sharma A, Burkitt-Wright E and Rustom R (2006):** Cinacalcet as an adjunct in the successful treatment of calciphylaxis. *Br J Dermatol*; 155(6):1295-97.
- Shiraishi N, Kitamura K, Miyoshi T, et al. (2006):** Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. *Am J Kidney*; 48(1):151-54.
- Smiley CM, Hanlon SU and Michel DM (2000):** Calciphylaxis in moderate renal insufficiency: Changing disease concepts. *Am J Nephrol*; 20: 324-28.
- Speer MY and Giachelli CM (2004):** Regulation of cardiovascular calcification. *Cardiovasc Pathol*; 13:63-70.
- Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G and Giachelli CM (2001):** Smooth muscle cell phenotypic transition associated with calcification: Upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. *Circ Res*; 89:1147-54.

References

- Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM and Thadhani R (2003):** Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. *N Engl J Med*; 349:446-56.
- Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, and Thadhani R (2005):** Activated injectable vitamin D and hemodialysis survival: A historical cohort study. *J Am Soc Nephrol* 16: 1115–1125.
- Tentori F, Hunt WC, Stidley CA, Rohrschreib MR, Bednick EJ, Meyer KB, Johnson HK, and Fager PG (2006):** Mortality risk among hemodialysis patients receiving different vitamin D analogs.
- Tintut Y, Parhami F, Bostrom K, Jackson SM and Demer LL (1998):** cAMP stimulates osteoblast-like differentiation of calcifying vascular cells: Potential signaling pathway for vascular calcification. *J Biol Chem*; 273:7547-53.
- Tintut Y, Patel J, Parhami F and Demer LL (2000):** Tumor necrosis factor α promotes in vitro calcification of vascular cells via the cAMP pathway. *Circulation*; 102:2636-42.
- Vassa N, Twardowski ZJ and Campbell J (1994):** Hyperbaric oxygen therapy in calciphylaxis-induced skin necrosis in a peritoneal dialysis patient. *Am J Kidney Dis*; 23(6):878-81.
- Velasco N, MacGregor MS, Innes A and MacKay IG (2006):** Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? *Nephrol Dial Transplant*; 21(7):1999-2004.
- Wada T, McKee MD, Stietz S, and Giachelli CM (1999):** Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin. *Circ Res* 84: 1–6.
- Wallin R, Cain D and Sane DC (1999):** Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and

References

proliferating vascular smooth muscle cells a cell system which resembles the system in bone cells. *Thromb Haemost*; 82:1764.

Wang HY, Yu CC and Huang CC (2004): Successful treatment of severe calciphylaxis in a hemodialysis patient using low-calcium dialysate and medical parathyroidectomy: case report and literature review. *Ren Fail*; 26(1):77-82.

Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R and Demer LL (1997): Active serum vitamin D levels are inversely correlated with coronary calcification. *Circulation*; 96: 1755-60.

Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, and Demer LL (1997): Active serum vitamin D levels are inversely correlated with coronary calcification. *Circulation* 96: 1755–1760.

Wolf M, Sterns RH and Hix JK, (2008): Calciphylaxis from nonuremic causes: a systematic review. *Clin J Am Soc Nephrol*. 1139-43.

Wong, JJ, Laumann, A and Martinez, M (2000): Calciphylaxis and antiphospholipid antibody syndrome. *J Am Acad Dermatol*; 42:849.

Yang H, Curinga G and Giachelli CM (2004): Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. *Kidney Int*; in press.

Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L and Port FK (2005): Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. *Kidney Int*; 67:1179-87.

References

References
